NANO Stock Overview
A clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nanobiotix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.75 |
| 52 Week High | €10.40 |
| 52 Week Low | €3.82 |
| Beta | 1.28 |
| 11 Month Change | 11.55% |
| 3 Month Change | -12.84% |
| 1 Year Change | -39.87% |
| 33 Year Change | -60.87% |
| 5 Year Change | -46.93% |
| Change since IPO | -23.39% |
Recent News & Updates
Recent updates
Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 29
Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%
May 14We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate
Apr 26Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?
May 11Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?
Dec 06Is Nanobiotix (EPA:NANO) Using Too Much Debt?
Jun 04How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?
Dec 22
Shareholder Returns
| NANO | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -2.6% | -3.2% | -2.4% |
| 1Y | -39.9% | -30.1% | -4.7% |
Return vs Industry: NANO underperformed the French Biotechs industry which returned -29.7% over the past year.
Return vs Market: NANO underperformed the French Market which returned -1.7% over the past year.
Price Volatility
| NANO volatility | |
|---|---|
| NANO Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.5% |
Stable Share Price: NANO's share price has been volatile over the past 3 months.
Volatility Over Time: NANO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 102 | Laurent Levy | www.nanobiotix.com |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. Fundamentals Summary
| NANO fundamental statistics | |
|---|---|
| Market cap | €225.17m |
| Earnings (TTM) | -€39.70m |
| Revenue (TTM) | €36.21m |
6.2x
P/S Ratio-5.7x
P/E RatioIs NANO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANO income statement (TTM) | |
|---|---|
| Revenue | €36.21m |
| Cost of Revenue | €0 |
| Gross Profit | €36.21m |
| Other Expenses | €75.91m |
| Earnings | -€39.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -109.64% |
| Debt/Equity Ratio | -2,467.9% |
How did NANO perform over the long term?
See historical performance and comparison